Guillermo Garcia-Manero, MD
Professor, Department of Leukemia, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes, Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Please join Guillermo Garcia-Manero, MD, from MD Anderson Cancer Center, as he describes the study design of a new phase 2/3 study evaluating oral azacitidine for the treatment of myelodysplastic syndromes.
Supported through funding by
To sign up for our newsletter or print publications, please enter your contact information below.
Subscribe to recieve the free, monthly TON print publication and TON weekly e‑newsletter.